Production of vaccines comprising inactivated SARS-CoV-2 viral particles
AssigneesColorado State University Research Foundation, Dynavax Technologies Corporation
InventorsRaymond P. Goodrich, Richard Bowen
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for inactivating a viral particle, the methods comprising contacting the viral particle with UV light in the presence of riboflavin. In some embodiments, the viral particle is a SARS-CoV-2 particle. Vaccine compositions comprising inactivated viral particles (e.g., inactivated SARS-CoV-2 particles) are also provided. In some embodiments, the vaccine compositions comprise an adjuvant capable of promoting a Th1-type immune response.
Claims12
A vaccine composition comprising an inactivated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral particle, wherein the composition comprises at least 100 picograms or more of SARS-CoV-2 spike protein, an adjuvant capable of promoting a Th1-type immune response, and a pharmaceutically acceptable carrier or excipient, wherein the SARS-CoV-2 viral particle is inactivated by exposure to a dose of UV light in the presence of exogenous riboflavin in a buffered solution, and wherein the dose of UV light is from 0.5 Joules/mL to 3.0 Joules/mL of the vaccine composition.
A vaccine composition comprising an inactivated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral particle;
- wherein the composition comprises at least 100 picograms or more of SARS-CoV-2 spike protein;
- an adjuvant capable of promoting a Th1-type immune response;
- and a pharmaceutically acceptable carrier or excipient;
- wherein the adjuvant is a phosphorothioate oligonucleotide comprising about 15 to about 30 nucleotides, wherein the SARS-CoV-2 viral particle is inactivated by exposure to a dose of UV light in the presence of exogenous riboflavin in a buffered solution, and wherein the dose of UV light is from 0.5 Joules/mL to 3.0 Joules/mL of the vaccine composition.
A vaccine composition comprising inactivated Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viral particle;
- wherein the composition comprises between 1 and 15 nanograms of SARS-CoV-2 spike protein;
- a phosphorothioate oligonucleotide adjuvant capable of promoting a Th1-type immune response;
- and a pharmaceutically acceptable carrier or excipient;
- wherein the SARS-CoV-2 genome comprises about 1 to about 30 oxidized guanine residues, the residues being oxidized by exposure to a dose of UV light in the presence of exogenous riboflavin in a buffered solution;
- wherein the structure of antigens on the viral particle is not substantially altered compared to SARS-CoV-2 viral particle that has not been inactivated, and wherein the dose of UV light is from 0.5 Joules/mL to 3.0 Joules/mL of the vaccine composition.
Dependencies are inferred from the claim text.